Surf Wiki
Save to docs
arts/music

From Surf Wiki (app.surf) — the open knowledge base

Lanicemine

Chemical compound

Chemical compound

Lanicemine (AZD6765) is a low-trapping NMDA receptor antagonist that was under development by AstraZeneca for the management of severe and treatment-resistant depression. Lanicemine differs from ketamine in that it is a low-trapping NMDA receptor antagonist, showing similar rapid-acting antidepressant effects to ketamine in clinical trials but with little or no psychotomimetic side effects. However, lanicemine did not meet study endpoints, and its development was terminated by AstraZeneca in 2013.

References

References

  1. "Lanicemine". AdisInsight.
  2. (May 2017). "New targets for rapid antidepressant action". Progress in Neurobiology.
  3. (August 2013). "A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression". Biological Psychiatry.
  4. Flowers, Sophie. "Return to growth: AstraZeneca's CEO Pascal Soriot says 2013 was year of "momentum" for the company".
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

abandoned-drugs phenyl-compounds nmda-receptor-antagonists 1,2-diarylethylamines 2-pyridyl-compounds
Want to explore this topic further?

Ask Mako anything about Lanicemine — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report